Cited 31 times in
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 백순명 | - |
dc.date.accessioned | 2019-09-20T07:22:38Z | - |
dc.date.available | 2019-09-20T07:22:38Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170856 | - |
dc.description.abstract | BACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients. Tamoxifen for 5 years was also given to patients > 50 years and those < 50 years with ER+ and/or progesterone receptor-positive (PR+) tumors. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Median follow-up time was 11.2 years. RESULTS: In univariate analyses, RS was a significant predictor of outcome. In multivariate analyses, RS remained a significant independent predictor of outcome beyond clinico-pathologic factors, age, and type of surgery (p < 0.001). In the study population (n = 1065), the disease-free survival (DFS) hazard ratio (HR) with adding P to AC was 0.87 (95% CI 0.72-1.05; p = 0.14). RS was not a significant predictor of P benefit: for DFS, HRs for adding P to AC in RS low, intermediate, and high subgroups were 1.01 (95% CI 0.69-1.47; p = 0.99), 0.84 (95% CI 0.62-1.14; p = 0.26), and 0.81 (95% CI 0.60-1.10; p = 0.21), respectively (interaction p = 0.64). Similar findings were observed for the other study endpoints. CONCLUSIONS: RS maintains significant prognostic impact in ER-positive, node-positive patients treated with adjuvant chemotherapy plus tamoxifen. However, RS did not significantly predict benefit from adding paclitaxel to AC chemotherapy. (Trial Registration: PDQ: NSABP-B-28). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | Breast Cancer Research and Treatment | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | BioMedical Science Institute (의생명과학부) | - |
dc.contributor.googleauthor | Eleftherios P. Mamounas | - |
dc.contributor.googleauthor | Gong Tang | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.contributor.googleauthor | Frederick L. Baehner | - |
dc.contributor.googleauthor | Qing Liu | - |
dc.contributor.googleauthor | Jong-Hyeon Jeong | - |
dc.contributor.googleauthor | Seong-Rim Kim | - |
dc.contributor.googleauthor | Steven M. Butler | - |
dc.contributor.googleauthor | Farid Jamshidian | - |
dc.contributor.googleauthor | Diana B. Cherbavaz | - |
dc.contributor.googleauthor | Amy P. Sing | - |
dc.contributor.googleauthor | Steven Shak | - |
dc.contributor.googleauthor | Thomas B. Julian | - |
dc.contributor.googleauthor | Barry C. Lembersky | - |
dc.contributor.googleauthor | D. Lawrence Wickerham | - |
dc.contributor.googleauthor | Joseph P. Costantino | - |
dc.contributor.googleauthor | Norman Wolmark | - |
dc.identifier.doi | 10.1007/s10549-017-4550-8 | - |
dc.contributor.localId | A01823 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 29128898 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Node-positive | - |
dc.subject.keyword | Prognosis and prediction | - |
dc.subject.keyword | Recurrence score | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | 백순명 | - |
dc.citation.volume | 168 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 69 | - |
dc.citation.endPage | 77 | - |
dc.identifier.bibliographicCitation | Breast Cancer Research and Treatment, Vol.168(1) : 69-77, 2018 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.